Loading...
If your product does not perform as described on this datasheet, we will refund or replace your product...
Read our guarantee »Products:Cell Biology >> Apoptosis >> Intracellular >> NFkB >> p52
Anti-NFkB p100 / p52 (phospho S869) antibody
See all NFkB p100 / p52 products (11) ...
Rabbit polyclonal to NFkB p100 / p52 (phospho S869)
Antibody detects endogenous levels of NFkB p100 / p52 protein only when phosphorylated at Serine 869.
WB, IHC-P, IP, ELISAmore details
Reacts with
Mouse, Rat, Human
Synthetic phosphopeptide derived from Human NFkB p100 / p52 around the phosphorylation site of serine 869.
WB: breast carcinoma tissue, extracts of Hela cells, MOLT cells and MDA-MB-435 cells treated with TNF alpha. IHC-P: breast carcinoma tissue.
Liquid
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Preservative: 0.02% Sodium Azide
Constituents: 50% Glycerol, PBS (without Mg2+ and Ca2+), 150mM Sodium chloride, pH 7.4
Concentration information loading...
Immunogen affinity purified
This antibody was affinity purified from rabbit antiserum by affinity chromatography using epitope specific phosphopeptide.
Polyclonal
IgG
Cancer >> Signal transduction >> Nuclear signaling >> NFkB pathway
Epigenetics and Nuclear Signaling >> Nuclear Signaling Pathways >> NFkB pathway
Epigenetics and Nuclear Signaling >> Transcription >> Other factors
Signal Transduction >> Signaling Pathway >> Nuclear Signaling >> NFkB Pathway
Cell Biology >> Apoptosis >> Intracellular >> NFkB >> p52
Our Abpromise guarantee covers the use of ab31475 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
ELISA: 1/10000.
IHC-P: 1/50 - 1/100.
IP: Use at an assay dependent dilution.
WB: 1/500 - 1/1000. Detects bands of approximately 67 and 105 kDa (predicted molecular weights: 54 and 97 kDa).
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. In a non-canonical activation pathway, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. The NF-kappa-B heterodimeric RelB-p52 complex is a transcriptional activator. The NF-kappa-B p52-p52 homodimer is a transcriptional repressor. NFKB2 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p100 and generation of p52 by a cotranslational processing. The proteasome-mediated process ensures the production of both p52 and p100 and preserves their independent function. p52 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. p52 and p100 are respectively the minor and major form; the processing of p100 being relatively poor. Isoform p49 is a subunit of the NF-kappa-B protein complex, which stimulates the HIV enhancer in synergy with p65.
Note=A chromosomal aberration involving NFKB2 is found in a case of B-cell non Hodgkin lymphoma (B-NHL). Translocation t(10;14)(q24;q32) with IGHA1. The resulting oncogene is also called Lyt-10C alpha variant.
Note=A chromosomal aberration involving NFKB2 is found in a cutaneous T-cell leukemia (C-TCL) cell line. This rearrangement produces the p80HT gene which encodes for a truncated 80 kDa protein (p80HT).
Note=In B-cell leukemia (B-CLL) cell line, LB40 and EB308, can be found after heterogeneous chromosomal aberrations, such as internal deletions.
Contains 7 ANK repeats.
Contains 1 death domain.
Contains 1 RHD (Rel-like) domain.
The C-terminus of p100 might be involved in cytoplasmic retention, inhibition of DNA-binding by p52 homodimers, and/or transcription activation.
The glycine-rich region (GRR) appears to be a critical element in the generation of p52.
While translation occurs, the particular unfolded structure after the GRR repeat promotes the generation of p52 making it an acceptable substrate for the proteasome. This process is known as cotranslational processing. The processed form is active and the unprocessed form acts as an inhibitor (I kappa B-like), being able to form cytosolic complexes with NF-kappa B, trapping it in the cytoplasm. Complete folding of the region downstream of the GRR repeat precludes processing.
Subsequent to MAP3K14-dependent serine phosphorylation, p100 polyubiquitination occurs then triggering its proteasome-dependent processing.
Constitutive processing is tightly suppressed by its C-terminal processing inhibitory domain, named PID, which contains the death domain.
Nucleus. Cytoplasm. Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor.
Target information above from: UniProt accessionQ00653
The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).
Immunohistochemistry (Paraffin-embedded sections) - NFkB p100 / p52 antibody (ab31475)

Ab31475, at a dilution of 1/50-1/100, staining NFkB p100 / p52 in paraffin embedded human breast carcinoma tissue by Immunohistochemistry.
Left image: Untreated.
Right image: Antibody pre incubated with synthesized phosphopeptide.
Western blot - NFkB p100 / p52 (phospho S869) antibody (ab31475)

All lanes : Anti-NFkB p100 / p52 (phospho S869) antibody (ab31475) at 1/500 dilution
Lane 1 : Extracts of Hela cells untreated (5-30ug).
Lane 2 : Extracts of MOLT cells untreated (5-30ug).
Lane 3 : Extracts of MDA-MB-435 cells treated with TNF alpha (5-30ug).
Secondary
goat-anti-rabbit IgG-AP-conjugate.
Predicted band size : 54 , 97 kDa
Observed band size : 67,105 kDa (why is the actual band size different from the predicted?)
ab31475 has not yet been referenced specifically in any publications.
Publishing research using ab31475? Please let us know so that we can cite the reference in this datasheet
Concentration of lot no. is
Concentration not available for this lot.
Find concentration of your lot:

Ab31475, at a dilution of 1/50-1/100, staining NFkB p100 / p52 in paraffin embedded human breast carcinoma tissue by Immunohistochemistry.
Left image: Untreated.
Right image: Antibody pre incubated with synthesized phosphopeptide.

All lanes : Anti-NFkB p100 / p52 (phospho S869) antibody (ab31475) at 1/500 dilution
Lane 1 : Extracts of Hela cells untreated (5-30ug).
Lane 2 : Extracts of MOLT cells untreated (5-30ug).
Lane 3 : Extracts of MDA-MB-435 cells treated with TNF alpha (5-30ug).
Secondary
goat-anti-rabbit IgG-AP-conjugate.
Predicted band size : 54 , 97 kDa
Observed band size : 67,105 kDa (why is the actual band size different from the predicted?)
0
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"
Call 01223 696 000 or contact us
